PT  - JOURNAL ARTICLE
AU  - Julie Dupouy
AU  - Aurore Palmaro
AU  - Mélina Fatséas
AU  - Marc Auriacombe
AU  - Joëlle Micallef
AU  - Stéphane Oustric
AU  - Maryse Lapeyre-Mestre
TI  - Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice: A 7-Year Cohort Study
AID  - 10.1370/afm.2098
DP  - 2017 Jul 01
TA  - The Annals of Family Medicine
PG  - 355--358
VI  - 15
IP  - 4
4099  - http://www.annfammed.org/content/15/4/355.short
4100  - http://www.annfammed.org/content/15/4/355.full
SO  - Ann Fam Med2017 Jul 01; 15
AB  - In France, most cases of opioid use disorder are treated with buprenorphine by general practitioners in private practice. Using reimbursement data of a representative sample of the French population, Echantillon Généraliste des Bénéficiaires, we investigated mortality during periods when patients were in and out of treatment in a cohort of 713 new users of buprenorphine having a mean (SD) follow-up of 4.5 (1.5) years. The mortality rate was 0.63 per 100 person-years (95% CI, 0.40–0.85) overall. In a multivariate Cox regression model, compared with being in treatment, being out of treatment was associated with a markedly increased risk of death (hazard ratio = 29.04; 95% CI, 10.04–83.99). Buprenorphine appears to be a strong protective factor against mortality.